The financing round was co-led by RA Capital Management and Forbion to support late-stage clinical development.
"We are delighted to secure the investment required to continue to advance inobrodib fully and as effectively as possible. This is a significant raise in a challenging market. Today's announcement is a testament to the data we have in hand, the clear clinical and commercial opportunity inobrodib represents, and the strength of our expanded team."
The Series A round was co-led by Forbion and General Atlantic to support clinical trials and portfolio expansion.
"People living with obesity and its complications deserve better options at each stage of their treatment journey. These include oral therapies with less frequent dosing regimens, which have the potential for improved efficacy and tolerability, and innovative combination therapies for healthier weight loss and—equally importantly—maintenance of metabolically healthy weight. We created Verdiva Bio to accelerate the development of differentiated medicines that address these significant unmet medical needs."
The private financing round was led by TCGX and Aisling Capital to fund clinical trials and commercial planning.
"We are grateful for the support of this group of leading healthcare investors for our work to bring potentially transformative treatment for mental health conditions to patients urgently in need of better options. We thank these investors for their confidence in our rigorous approach to building a strong base of evidence for the potential of COMP360 psilocybin treatment to help people with treatment-resistant depression (TRD), post-traumatic stress disorder, and anorexia nervosa."
